Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epilepsy
Pharma
SK eyes Xcopri expansion with phase 3 win in new seizure type
SK Biopharmaceutical is targeting an indication in primary generalized tonic-clonic seizures for Xcopri after its 2019 approval for focal seizures.
Zoey Becker
Sep 17, 2025 11:32am
UCB's Fintepla shows potential to treat a 3rd epilepsy disorder
Jun 27, 2025 11:28am
Takeda, Enhertu, East Asian American execs—Fierce Pharma Asia
Jan 31, 2025 8:53am
Jazz hunts for new CEO as longtime chief Cozadd eyes retirement
Dec 17, 2024 10:49am
Eisai ends lorcaserin development in Dravet syndrome
Nov 18, 2024 10:18am
Jazz's Epidiolex fails trial in treatment-resistant epilepsies
Aug 23, 2024 10:18am
